Amarin, FDA Seek More Time For Off-Label Settlement
This article was originally published in Scrip
Executive Summary
Amarin Corp. and the FDA have again asked a New York court to stay the proceedings in the ongoing court battle involving off-label promotion of the company's fish oil pill Vascepa (icosapent ethyl), declaring they're in the midst of exploring the possibility of a settlement and need another month.